Brief: UCB: New Data Supports Earlier Use Of Bimzelx For Treating Hidradenitis Suppurativa
30/09/2026 06:03
BRIEF-UCB: New Data Supports Earlier Use Of Bimzelx For Treating Hidradenitis Suppurativa Sept 30 (Reuters) - Ucb SA UCB.BR:
NEW DATA AT EADV 2026 SUPPORTING EARLIER USE OF BIMZELX (BIMEKIZUMAB) FOR TREATING HIDRADENITIS SUPPURATIVA
BIOLOGIC-NAIVE PATIENTS DEMONSTRATED IMPROVED DRAINING TUNNEL OUTCOMES
IMPROVEMENTS BEYOND DRAINING TUNNELS TO TOTAL TUNNEL COUNT
ADDITIONAL LONG-TERM, THREE-YEAR DATA SHOWED TREATMENT IN PEOPLE LIVING WITH MODERATE TO SEVERE HS ASSOCIATED WITH SUSTAINED IMPROVEMENTS IN QUALITY OF LIFE
Source text: ID:nPLX217Q33
Further company coverage: UCB.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on UCB SA
See all newsUCB tops STOXX after guidance upgrade on better drug sales
UCB lifts 2026 outlook again as Bimzelx demand eases investor concerns (updated)
UCB upgrades 2026 guidance on strong US Bimzelx sales
Brief: UCB Eyes Low- To Mid-Forties FY Adjusted EBITDA Growth
Brief: UCB Annouces FDA Approval For Zilbrysq Autoinjector Self-Administration For Adults Living With Generalized Myasthenia Gravis